Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 8.9% – What’s Next?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) fell 8.9% on Monday . The stock traded as low as $1.32 and last traded at $1.33. 579,108 shares changed hands during mid-day trading, an increase of 171% from the average session volume of 213,869 shares. The stock had previously closed at $1.46.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Telomir Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Telomir Pharmaceuticals Price Performance

The stock has a market cap of $45.73 million, a PE ratio of -3.59 and a beta of -0.46. The business has a fifty day moving average of $1.40 and a 200-day moving average of $1.49.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its earnings results on Monday, November 10th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. As a group, equities research analysts predict that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current year.

Institutional Trading of Telomir Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in TELO. Bank of America Corp DE lifted its position in Telomir Pharmaceuticals by 283.9% during the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after acquiring an additional 10,880 shares during the last quarter. Nuveen LLC purchased a new position in Telomir Pharmaceuticals in the first quarter worth $81,000. HighTower Advisors LLC acquired a new position in shares of Telomir Pharmaceuticals during the first quarter worth $139,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter valued at $81,000. Finally, Marshall Wace LLP acquired a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth $95,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.